{
  "symbol": "CTXR",
  "company_name": "Citius Pharmaceuticals Inc",
  "ir_website": "https://citiuspharma.com/investors/default.aspx",
  "structured_data": [
    {
      "section_name": "Press Releases & Media",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://citiuspharma.com/investors/news-media/news/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Press Releases\n\nSelecting a year value will change the news content\n\nSelect Year:\n\nLoading\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Media",
          "url": "https://citiuspharma.com/investors/news-media/media/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Media\n\n##  Media Coverage\n\nSelecting a year value will change the news content\n\nSelect Year:\n\n20242023202220212020201920172016\n\nShowing 2024 undefined News\n\n03/18/2024 \n\n[Targeted Oncology: FDA Accepts BLA Resubmission of Denileukin Diftitox for R/R CTCL](https://www.targetedonc.com/view/fda-accepts-bla-resubmission-of-denileukin-diftitox-for-r-r-ctcl)\n\n[Read More](https://www.targetedonc.com/view/fda-accepts-bla-resubmission-of-denileukin-diftitox-for-r-r-ctcl)\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "Events",
          "url": "https://citiuspharma.com/investors/events-and-presentations/events/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Events\n\n##  Upcoming Events\n\n##  Archived Events\n\nSelecting a year value will change the event content\n\nSelect year:\n\nLoading...\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Corporate Presentation",
          "url": "https://citiuspharma.com/investors/events-and-presentations/presentations/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Corporate Presentation\n\n##  Featured Presentation\n\nLoading ...\n\n##  Fact Sheet\n\nLoading ...\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        }
      ]
    },
    {
      "section_name": "Stock Information",
      "links": [
        {
          "title": "Analyst Coverage",
          "url": "https://citiuspharma.com/investors/stock-information/analyst-coverage/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Analyst Coverage\n\nAnalyst Coverage Table **Firm** | **Analyst**  \n---|---  \nE.F. Hutton| Jason Kolbert  \nH.C. Wainwright| Vernon Bernadino  \nMaxim Group| Michael OkunewitchJason McCarthy, Ph.D.  \n  \n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Stock Quote",
          "url": "https://citiuspharma.com/investors/stock-information/default.aspx#stock-quote",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Stock Information\n\n## Stock Quote\n\nLoading ...\n\n## Stock Chart\n\n## Historical Stock Quote\n\n## Investment Calculator\n\nAmount ($)\n\nStart Date: Investment calculator calendar\n\nEnd Date: Investment calculator calendar\n\n### Compare to:\n\nS&P 500\n\nNasdaq 100\n\nDow 30\n\nOther\n\nReinvest Dividends\n\nCalculate Investment\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n\nPrevNext\n\nJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovember200420052006200720082009201020112012201320142015201620172018201920202021202220232024\n\nS| M| T| W| T| F| S  \n---|---|---|---|---|---|---  \n[1](#)| [2](#)  \n[3](#)| [4](#)| [5](#)| [6](#)| [7](#)| [8](#)| [9](#)  \n[10](#)| [11](#)| [12](#)| [13](#)| [14](#)| [15](#)| [16](#)  \n[17](#)| [18](#)| [19](#)| [20](#)| [21](#)| [22](#)| [23](#)  \n[24](#)| [25](#)| [26](#)| [27](#)| [28](#)| [29](#)| [30](#)  \n  \nTodayClose\n"
        },
        {
          "title": "Stock Chart",
          "url": "https://citiuspharma.com/investors/stock-information/default.aspx#stock-chart",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Stock Information\n\n## Stock Quote\n\n### Nasdaq: CTXR\n\nPrice\n\n$3.32\n\nVolume\n\n180,476\n\nChange\n\n-0.28\n\n% Change\n\n-7.78%\n\nToday's Open\n\n$3.49\n\nPrevious Close\n\n$3.60\n\nIntraday High\n\n$3.60\n\nIntraday Low\n\n$3.26\n\n52 Week High\n\n$26.75\n\n52 Week Low\n\n$2.55\n\nPricing delayed by 20 minutes. Last Updated 11/29/2024 1:00 PM\n\n## Stock Chart\n\nView stock chart as data table\n\n### Chart\n\nCombination chart with 4 data series.\n\nThe chart shows company stock prices from begin year to present.\n\nThe chart has 2 X axes displaying Time, and navigator-x-axis.\n\nThe chart has 3 Y axes displaying values, values, and navigator-y-axis.\n\nFrom:  Calendar button To:  Calendar button\n\nZoomView 1 monthView 3 monthsView 6 monthsView year to dateView 1 yearView all\n\nCreated with Highcharts 12.0.1ZoomView 1 month1mView 3 months3mView 6 months6mView year to dateYTDView 1 year1yView allAll3m ▾Nasdaq:CTXRNews ReleasesSep 2Sep 9Sep 16Sep 23Sep 30Oct 7Oct 14Oct 21Oct 28Nov 4Nov 11Nov 18Nov 252019​20192020​20202021​20212022​20222023​20232024​202401.22.43.64.805M10M15M20M\n\nEnd of interactive chart.\n\nXNAS:CTXR,Nasdaq:CTXR historical stock dataStock Date| Stock Price  \n---|---  \nNovember 29, 2024| $3.32  \nNovember 27, 2024| $3.6  \nNovember 26, 2024| $4.15  \nNovember 25, 2024| $3.3375  \nNovember 22, 2024| $0.1338  \nNovember 21, 2024| $0.1651  \nNovember 20, 2024| $0.1699  \nNovember 19, 2024| $0.1918  \nNovember 18, 2024| $0.2242  \nNovember 15, 2024| $0.2  \nNovember 14, 2024| $0.3284  \nNovember 13, 2024| $0.3857  \nNovember 12, 2024| $0.4822  \nNovember 11, 2024| $0.4492  \nNovember 08, 2024| $0.4115  \nNovember 07, 2024| $0.3822  \nNovember 06, 2024| $0.347  \nNovember 05, 2024| $0.3497  \nNovember 04, 2024| $0.349  \nNovember 01, 2024| $0.3589  \nOctober 31, 2024| $0.3727  \nOctober 30, 2024| $0.4047  \nOctober 29, 2024| $0.3904  \nOctober 28, 2024| $0.3699  \nOctober 25, 2024| $0.364  \nOctober 24, 2024| $0.346  \nOctober 23, 2024| $0.3571  \nOctober 22, 2024| $0.369  \nOctober 21, 2024| $0.3842  \nOctober 18, 2024| $0.391  \nOctober 17, 2024| $0.41  \nOctober 16, 2024| $0.412  \nOctober 15, 2024| $0.3741  \nOctober 14, 2024| $0.3555  \nOctober 11, 2024| $0.3672  \nOctober 10, 2024| $0.4001  \nOctober 09, 2024| $0.3922  \nOctober 08, 2024| $0.3884  \nOctober 07, 2024| $0.395  \nOctober 04, 2024| $0.434  \nOctober 03, 2024| $0.4456  \nOctober 02, 2024| $0.4695  \nOctober 01, 2024| $0.4681  \nSeptember 30, 2024| $0.5006  \nSeptember 27, 2024| $0.5219  \nSeptember 26, 2024| $0.517  \nSeptember 25, 2024| $0.5163  \nSeptember 24, 2024| $0.54  \nSeptember 23, 2024| $0.5509  \nSeptember 20, 2024| $0.5699  \nSeptember 19, 2024| $0.5481  \nSeptember 18, 2024| $0.51  \nSeptember 17, 2024| $0.501  \nSeptember 16, 2024| $0.5048  \nSeptember 13, 2024| $0.5199  \nSeptember 12, 2024| $0.5175  \nSeptember 11, 2024| $0.53  \nSeptember 10, 2024| $0.5381  \nSeptember 09, 2024| $0.526  \nSeptember 06, 2024| $0.53  \nSeptember 05, 2024| $0.54  \nSeptember 04, 2024| $0.55  \nSeptember 03, 2024| $0.5471  \nAugust 30, 2024| $0.57  \nAugust 29, 2024| $0.5666  \nAugust 28, 2024| $0.5775  \nAugust 27, 2024| $0.5919  \nAugust 26, 2024| $0.68  \nAugust 23, 2024| $0.595  \nAugust 22, 2024| $0.5733  \nAugust 21, 2024| $0.5976  \nAugust 20, 2024| $0.6033  \nAugust 19, 2024| $0.6402  \nAugust 16, 2024| $0.6031  \nAugust 15, 2024| $0.5863  \nAugust 14, 2024| $0.5901  \nAugust 13, 2024| $0.6104  \nAugust 12, 2024| $0.6912  \nAugust 09, 2024| $0.78  \nAugust 08, 2024| $0.89  \nAugust 07, 2024| $0.9059  \nAugust 06, 2024| $1.02  \nAugust 05, 2024| $0.9324  \nAugust 02, 2024| $0.9065  \nAugust 01, 2024| $0.9054  \nJuly 31, 2024| $0.905  \nJuly 30, 2024| $0.931  \nJuly 29, 2024| $0.9852  \nJuly 26, 2024| $0.96  \nJuly 25, 2024| $0.9309  \nJuly 24, 2024| $0.928  \nJuly 23, 2024| $0.9301  \nJuly 22, 2024| $0.8522  \nJuly 19, 2024| $0.7918  \nJuly 18, 2024| $0.8266  \nJuly 17, 2024| $0.82  \nJuly 16, 2024| $0.85  \nJuly 15, 2024| $0.7653  \nJuly 12, 2024| $0.7339  \nJuly 11, 2024| $0.7723  \nJuly 10, 2024| $0.7458  \n  \n## Historical Stock Quote\n\nLookup Date: 20242023202220212020201920182017201620152014JanFebMarAprMayJunJulAugSepOctNovDec123456789101112131415161718192021222324252627282930Look Up\n\n### Stock Quote: Nasdaq: CTXR\n\nDay's Open\n\n$3.49\n\nClosing Price\n\n$3.32\n\nIntraday Low\n\n$3.26\n\nIntraday High\n\n$3.60\n\nVolume\n\n180,476\n\n## Investment Calculator\n\nAmount ($)\n\nStart Date: Investment calculator calendar\n\nEnd Date: Investment calculator calendar\n\n### Compare to:\n\nS&P 500\n\nNasdaq 100\n\nDow 30\n\nOther\n\nReinvest Dividends\n\nCalculate Investment\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n\nPrevNext\n\nJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovember2018201920202021202220232024\n\nSu| Mo| Tu| We| Th| Fr| Sa  \n---|---|---|---|---|---|---  \n[1](#)| [2](#)  \n[3](#)| [4](#)| [5](#)| [6](#)| [7](#)| [8](#)| [9](#)  \n[10](#)| [11](#)| [12](#)| [13](#)| [14](#)| [15](#)| [16](#)  \n[17](#)| [18](#)| [19](#)| [20](#)| [21](#)| [22](#)| [23](#)  \n[24](#)| [25](#)| [26](#)| [27](#)| [28](#)| [29](#)| 30  \n  \nClose\n"
        },
        {
          "title": "Historical Stock Quote",
          "url": "https://citiuspharma.com/investors/stock-information/default.aspx#stock-historical",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Stock Information\n\n## Stock Quote\n\n### Nasdaq: CTXR\n\nPrice\n\n$3.32\n\nVolume\n\n180,476\n\nChange\n\n-0.28\n\n% Change\n\n-7.78%\n\nToday's Open\n\n$3.49\n\nPrevious Close\n\n$3.60\n\nIntraday High\n\n$3.60\n\nIntraday Low\n\n$3.26\n\n52 Week High\n\n$26.75\n\n52 Week Low\n\n$2.55\n\nPricing delayed by 20 minutes. Last Updated 11/29/2024 1:00 PM\n\n## Stock Chart\n\n## Historical Stock Quote\n\nLookup Date: 20242023202220212020201920182017201620152014JanFebMarAprMayJunJulAugSepOctNovDec123456789101112131415161718192021222324252627282930Look Up\n\n### Stock Quote: Nasdaq: CTXR\n\nLoading historical data...\n\n## Investment Calculator\n\nAmount ($)\n\nStart Date: Investment calculator calendar\n\nEnd Date: Investment calculator calendar\n\n### Compare to:\n\nS&P 500\n\nNasdaq 100\n\nDow 30\n\nOther\n\nReinvest Dividends\n\nCalculate Investment\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n\nPrevNext\n\nJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovember200420052006200720082009201020112012201320142015201620172018201920202021202220232024\n\nS| M| T| W| T| F| S  \n---|---|---|---|---|---|---  \n[1](#)| [2](#)  \n[3](#)| [4](#)| [5](#)| [6](#)| [7](#)| [8](#)| [9](#)  \n[10](#)| [11](#)| [12](#)| [13](#)| [14](#)| [15](#)| [16](#)  \n[17](#)| [18](#)| [19](#)| [20](#)| [21](#)| [22](#)| [23](#)  \n[24](#)| [25](#)| [26](#)| [27](#)| [28](#)| [29](#)| [30](#)  \n  \nTodayClose\n"
        },
        {
          "title": "Investment Calculator",
          "url": "https://citiuspharma.com/investors/stock-information/default.aspx#calculator",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Stock Information\n\n## Stock Quote\n\nLoading ...\n\n## Stock Chart\n\n## Historical Stock Quote\n\n## Investment Calculator\n\nAmount ($)\n\nStart Date: Investment calculator calendar\n\nEnd Date: Investment calculator calendar\n\n### Compare to:\n\nS&P 500\n\nNasdaq 100\n\nDow 30\n\nOther\n\nReinvest Dividends\n\nCalculate Investment\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n\nPrevNext\n\nJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovember200420052006200720082009201020112012201320142015201620172018201920202021202220232024\n\nS| M| T| W| T| F| S  \n---|---|---|---|---|---|---  \n[1](#)| [2](#)  \n[3](#)| [4](#)| [5](#)| [6](#)| [7](#)| [8](#)| [9](#)  \n[10](#)| [11](#)| [12](#)| [13](#)| [14](#)| [15](#)| [16](#)  \n[17](#)| [18](#)| [19](#)| [20](#)| [21](#)| [22](#)| [23](#)  \n[24](#)| [25](#)| [26](#)| [27](#)| [28](#)| [29](#)| [30](#)  \n  \nTodayClose\n"
        }
      ]
    },
    {
      "section_name": "Financials & SEC Filings",
      "links": [
        {
          "title": "Quarterly Results",
          "url": "https://citiuspharma.com/investors/financials/quarterly-results/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Quarterly Results\n\n## Financial Summary Table\n\nshowing 1-3 of 14\n\nFinancial summary table containing documents grouped by year, quarter and typeFiscal Year  \n---  \n2024|  2023|  2022|  2021|  2020|  2019|  2018|  2017|  2016|  2015|  2014|  2013|  2012|  2011  \nPress Release| [Q1 ](https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-First-Quarter-2024-Financial-Results-and-Provides-Business-Update/default.aspx)[Q2 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Second-Quarter-2024-Financial-Results-and-Provides-Business-Update)[Q3 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [Q1 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2023/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-First-Quarter-2023-Financial-Results-and-Provides-Business-Update)[Q2 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2023/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update)[Q3 ](https://citiuspharma.com/investors/news-media/news/release-details/2023/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update/default.aspx)[Q4 ](https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Full-Year-2023-Financial-Results-and-Provides-Business-Update/default.aspx)| [Q1 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2022/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-First-Quarter-2022-Financial-Results-and-Provides-Business-Update)[Q2 ](https://citiuspharma.com/investors/news-media/news/release-details/2022/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Second-Quarter-2022-Financial-Results-and-Provides-Business-Update/default.aspx)[Q3 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2022/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Third-Quarter-2022-Financial-Results-and-Provides-Business-Update)[Q4 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2022/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Full-Year-2022-Financial-Results-and-Provides-Business-Update)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[Q2 ](/investors/news-media/news/release-details/2021/Citius-Pharmaceuticals-Inc.-Reports-Second-Fiscal-Quarter-2021-Financial-Results-and-Provides-General-Business-Update-2021-5-13-2021-5-13/default.aspx)[Q3 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2021/Citius-Pharmaceuticals-Inc.-Reports-Third-Fiscal-Quarter-2021-Financial-Results-and-Provides-General-Business-Update)[Q4 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2021/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Full-Year-2021-Financial-Results-and-Provides-Business-Update)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)  \nFinancial Statement| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2024/q1/fb696874-68da-4a59-ae30-e05dd44650ac.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2024/q2/27eb5e9b-423e-4766-af27-75236283b8f5.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2024/q3/406ac888-5c0a-4f17-a6e5-7c492704626d.pdf)[ Q4 Q4 Financial Statement not available](javascript:void\\(0\\);)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2023/q1/2b153e8b-ed0b-4e0d-a96c-2c3d5924f178.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2023/q2/b26e7090-a86a-433a-8ce4-1dac0bd100f5.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2023/q2/8d0aefb8-ce89-4d3d-a270-96b8c36d4ee5.pdf)[ Q4 Q4 Financial Statement not available](javascript:void\\(0\\);)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2022/q1/478d267f-353b-4b1f-bc92-a36378566613.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2022/q2/7ba9e69d-de91-4133-a0e3-c99f458a0b48.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2022/q3/4b6eefd8-47f6-4fdf-8614-7c08364dcf07.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2022/q4/63bf251a-c552-4de7-84a9-a2aba6b6788e.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2021/q1/0001213900-21-008453.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2021/q2/0001213900-21-025920.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2021/q3/0001213900-21-042071.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2021/q4/f10k2021_citiuspharmaEDGAR8_Bannerless.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2020/q1/0001213900-20-003577.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2020/q2/0001213900-20-012286.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2020/q3/0001213900-20-022331.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2020/ar/0001213900-20-043004.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2019/q1/0001213900-19-002563.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2019/q2/0001213900-19-008833.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2019/q3/0001213900-19-015793.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2019/ar/0001213900-19-026259.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2018/q1/0001213900-18-001880.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2018/q2/0001213900-18-005952.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2018/q3/0001213900-18-011072.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2018/ar/0001213900-18-017214.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2017/q1/0001477932-17-000773.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2017/q2/0001477932-17-002308.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2017/q3/0001477932-17-003946.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2017/ar/0001213900-17-013191.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2016/q1/0001477932-16-008554.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2016/q2/0001477932-16-010425.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2016/q3/0001477932-16-011894.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2016/ar/0001477932-16-014315.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2015/q1/0001477932-15-001225.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2015/q2/0001477932-15-003063.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2015/q3/0001477932-15-005025.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2015/ar/0001477932-15-007617.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2014/q1/0001185185-14-000338.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2014/q2/0001185185-14-001283.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2014/q3/0001185185-14-002170.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2014/ar/0001477932-14-007353.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2013/q1/0001185185-13-000267.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2013/q2/0001185185-13-001079.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2013/q3/0001185185-13-001832.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2013/ar/0001185185-13-002725.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2012/q1/0001185185-12-000229.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2012/q2/0001185185-12-000973.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2012/q3/0001185185-12-001826.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2012/ar/0001185185-12-002886.pdf)| [ Q1 Q1 Financial Statement not available](javascript:void\\(0\\);)[ Q2 Q2 Financial Statement not available](javascript:void\\(0\\);)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2011/q3/0001019687-11-002825.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2011/ar/0001185185-11-002313.pdf)  \nAnnual Report| [ AR AR Annual Report not available](javascript:void\\(0\\);)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2023/ar/a038a3e4-64d9-4c88-a943-707e5006587c.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2022/q4/63bf251a-c552-4de7-84a9-a2aba6b6788e.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2021/ar/f10k2021_citiuspharmaEDGAR8_Bannerless.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2020/ar/0001213900-20-043004.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2019/ar/0001213900-19-026259.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2018/ar/0001213900-18-017214.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2017/ar/0001213900-17-013191.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2016/ar/0001477932-16-014315.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2015/ar/0001477932-15-007617.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2014/ar/0001477932-14-007353.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2013/ar/0001185185-13-002725.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2012/ar/0001185185-12-002886.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2011/ar/0001185185-11-002313.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)  \n  \n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Annual Reports",
          "url": "https://citiuspharma.com/investors/financials/annual-reports/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Annual Reports\n\n2023 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2023/ar/a038a3e4-64d9-4c88-a943-707e5006587c@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2023/ar/a038a3e4-64d9-4c88-a943-707e5006587c.pdf)\n\nArchived Reports\n\n2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011\n\n2022 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2022/q4/63bf251a-c552-4de7-84a9-a2aba6b6788e@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2022/q4/63bf251a-c552-4de7-84a9-a2aba6b6788e.pdf)\n\n2021 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2020/ar/0001213900-20-043004@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2021/ar/f10k2021_citiuspharmaEDGAR8_Bannerless.pdf)\n\n2020 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2020/ar/0001213900-20-043004@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2020/ar/0001213900-20-043004.pdf)\n\n2019 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2019/ar/0001213900-19-026259@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2019/ar/0001213900-19-026259.pdf)\n\n2018 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2018/ar/0001213900-18-017214@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2018/ar/0001213900-18-017214.pdf)\n\n2017 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2017/ar/0001213900-17-013191@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2017/ar/0001213900-17-013191.pdf)\n\n2016 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2016/ar/0001477932-16-014315@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2016/ar/0001477932-16-014315.pdf)\n\n2015 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2015/ar/0001477932-15-007617@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2015/ar/0001477932-15-007617.pdf)\n\n2014 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2014/ar/0001477932-14-007353@2x.png)\n\n[10-KT](//s28.q4cdn.com/169506891/files/doc_financials/2014/ar/0001477932-14-007353.pdf)[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2014/ar/0001185185-14-000261.pdf)\n\n2013 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2013/ar/0001185185-13-002725@2x.png)\n\n[NT 10-K](//s28.q4cdn.com/169506891/files/doc_financials/2013/ar/0001185185-13-002725.pdf)[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2013/ar/0001185185-13-000090.pdf)\n\n2012 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2012/ar/0001185185-12-002886@2x.png)\n\n[NT 10-K](//s28.q4cdn.com/169506891/files/doc_financials/2012/ar/0001185185-12-002886.pdf)[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2012/ar/0001185185-12-000067.pdf)\n\n2011 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2011/ar/0001185185-11-002313@2x.png)\n\n[NT 10-K](//s28.q4cdn.com/169506891/files/doc_financials/2011/ar/0001185185-11-002313.pdf)\n\nView More\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "SEC Filings",
          "url": "https://citiuspharma.com/investors/financials/sec-filings/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# SEC Filings\n\nSelecting the value will change the page content\n\nSelect Year: Filter filing type: All Form Types Annual Filings Quarterly Filings Current Reports Proxy Filings Registration Statements Section 16 Filings Other\n\nDate Filing Type Filing Description Download / View\n\nLoading ...\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        }
      ]
    },
    {
      "section_name": "Governance",
      "links": [
        {
          "title": "Management Team",
          "url": "https://citiuspharma.com/about/management-team/default.aspx",
          "content": "Citius Pharmaceuticals, Inc. - About - Management Team \n\n[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Management Team\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Board of Directors",
          "url": "https://citiuspharma.com/about/board-of-directors/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Board of Directors\n\n**Board Diversity Matrix (as of December 31, 2023)**\n\nTotal Number of Directors | 6  \n---|---  \nFemale | Male | Non-Binary | Did Not disclose Gender  \nPart I: Gender Identity  \nDirectors | 1 | 5 | - | -  \nPart II: Demographic Background  \nAfrican American or Black | - | - | - | -  \nAlaskan Native or Native American | - | - | - | -  \nAsian | - | 1 | - | -  \nHispanic or Latinx | - | - | - | -  \nNative Hawaiian or Pacific Islander | - | - | - | -  \nWhite | 1 | 4 | - | -  \nTwo or More Races or Ethnicities | - | - | - | -  \nLGBTQ+ | - | - | - | -  \nDid Not Disclose Demographic Background | - | - | - | -  \n  \n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Committee Composition",
          "url": "https://citiuspharma.com/investors/governance/committee-composition/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Committee Composition\n\nAudit Committee  |  Compensation Committee  |  Nominating and Corporate Governance Committee   \n---|---|---  \nLeonard Mazur  \nMyron Holubiak  \nSuren Dutia  \nEugene Holuka, MD  \nCarol Webb  \nDennis M. McGrath  \n  \n#### \n\nAudit Committee\n\nSuren Dutia\n\nCarol Webb\n\nDennis M. McGrath\n\n#### \n\nCompensation Committee\n\nEugene Holuka, MD\n\nCarol Webb\n\n#### \n\nNominating and Corporate Governance Committee\n\nEugene Holuka, MD\n\nCarol Webb\n\nDennis M. McGrath\n\n  * Board Chair\n  * Committee Member\n  * Committee Chair\n\n\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Governance Documents",
          "url": "https://citiuspharma.com/investors/governance/governance-documents/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Governance Documents\n\nDownload item year list\n\nDownload Description\n\n[ Audit and Risk Committee Charter PDF Format (opens in new window) ](//s28.q4cdn.com/169506891/files/doc_downloads/governance/Audit_Committee_Charter.pdf)\n\n96 KB\n\n[ Compensation Committee Charter PDF Format (opens in new window) ](//s28.q4cdn.com/169506891/files/doc_downloads/governance/2022/08/Compensation-Committee-Charter-2022-\\(1\\).pdf)\n\n83 KB\n\n[ Nominating and Governance Committee Charter PDF Format (opens in new window) ](//s28.q4cdn.com/169506891/files/doc_downloads/governance/Nom__Gov_Committee_Charter.pdf)\n\n74 KB\n\n[ Corporate Communications Policy PDF Format (opens in new window) ](//s28.q4cdn.com/169506891/files/doc_downloads/governance/Corporate_Communications_Policy.pdf)\n\n89 KB\n\n[ Insider Trading Policy PDF Format (opens in new window) ](//s28.q4cdn.com/169506891/files/doc_downloads/governance/Insider_Trading_Policy.pdf)\n\n108 KB\n\n[ Code of Ethics PDF Format (opens in new window) ](//s28.q4cdn.com/169506891/files/doc_downloads/governance/Code_of_Ethics.pdf)\n\n79 KB\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        }
      ]
    },
    {
      "section_name": "Investor Resources",
      "links": [
        {
          "title": "Investor FAQs",
          "url": "https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Investor FAQs\n\nDisplay All\n\n#### \n\nWhat is Citius Pharmaceuticals, Inc.'s ticker symbol?\n\nCTXR\n\n#### \n\nWhere is Citius Pharmaceuticals, Inc. stock traded?\n\nOur stock is traded on the Nasdaq exchange.\n\n#### \n\nWhen was Citius Pharmaceuticals, Inc. incorporated?\n\n2010\n\n#### \n\nWhen did Citius Pharmaceuticals, Inc. become a public company?\n\nSeptember 2014\n\n#### \n\nWhere is Citius Pharmaceuticals, Inc. located?\n\n11 Commerce Drive, First Floor Cranford, NJ 07016\n\n#### \n\nWhen is Citius Pharmaceuticals, Inc.'s fiscal year end?\n\nSeptember 30th\n\n#### \n\nWho is Citius Pharmaceuticals, Inc.'s transfer agent?\n\nVStock Transfer LLC 18 Lafayette Place Woodmere, NY 11598 T: [212-828-8436](tel:212-828-8436) [www.vstocktransfer.com](http://www.vstocktransfer.com)\n\n#### \n\nWho is Citius Pharmaceuticals, Inc.'s independent auditor?\n\nWolf & Company, P.C. 99 High Street Boston, MA 02110\n\n#### \n\nWho is Citius Pharmaceuticals, Inc.'s outside legal counsel?\n\nWyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail Suite 300 Raleigh, NC 27607 [www.wyrick.com](http://www.wyrick.com)\n\n#### \n\nWhen did Citius acquire Leonard Meron Biosciences (LMB)?\n\nOn March 30, 2016, Citius acquired Leonard-Meron Biosciences, Inc. (“LMB”) as a wholly-owned subsidiary. The Company acquired all of the outstanding stock of LMB by issuing shares of its common stock.\n\n#### \n\nWhom can I contact for general information about Citius Pharmaceuticals, Inc.?\n\nCitius Pharmaceuticals, Inc. Tel: [(908) 967-6677](tel:\\(908\\) 967-6677) Email: info@citiuspharma.com\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Information Request Form",
          "url": "https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Information Request Form\n\nThe following errors must be corrected\n\n• First Name is required\n\n• Last Name is required\n\n• Company Name is required\n\n• Email Address is required\n\n• Phone Number is required\n\n• State/ Province is required\n\n• Country is required\n\n• Information Request is required\n\n• Are you an investor? is required\n\nFirst Name*\n\nLast Name*\n\nCompany Name*\n\nEmail Address*\n\nPhone Number*\n\nState/ Province*\n\nCountry*AfghanistanAlbaniaAlgeriaAndorraAngolaAntigua & BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBhutanBoliviaBosnia & HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurmaBurundiCambodiaCameroonCanadaCape VerdeCentral African RepublicChadChileChinaColombiaComorosCongo (Brazzaville)Congo (Kinshasa)Costa RicaCôte d'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFijiFinlandFranceGabonGambiaGeorgiaGermanyGhanaGreeceGrenadaGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMoroccoNamibiaNauruNepalNetherlandsNew ZealandNicaraguaNigerNigeriaNorth KoreaNorwayOmanPakistanPalauPanamaPapua New GuineaParaguayPeruPhilippinesPolandPortugalQatarRomaniaRussiaRwandaSaint LuciaSaint Vincent and the GrenadinesSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSeychellesSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth KoreaSpainSri LankaSt. Kits and NevisSudanSurinameSwazilandSwedenSwitzerlandSyriaTajikistanTanzaniaThailandThe BahamasTogoTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaVietnamWestern SamoaYemenZaireZambiaZimbabwe\n\nInformation Request*\n\nAre you an investor?*\n\n  * I am an investor\n  * I am not an investor\n\n\n\nSubmit\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Investor Email Alerts",
          "url": "https://citiuspharma.com/investors/investor-resources/investor-email-alerts/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Investor Email Alerts\n\n## Subscribe To Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\nFor further information on how we protect your information, please refer to our [Disclaimer](/privacy-policy/default.aspx).\n\n## Unsubscribe From Investor Email Alerts\n\nTo opt-out of investor email alerts, please enter your email address in the field below and you will be removed from all investor relations email alerts to which you are subscribed. After submitting your email, you will receive a confirmation email to the requested email address. You must click the confirmation link in order to complete your request to unsubscribe. You can elect to receive investor alerts at any time you would like.\n\n* Required\n\nEmail Address *  \n---  \n  \nUnsubscribe\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Investor Contacts",
          "url": "https://citiuspharma.com/investors/investor-resources/investor-contacts/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Investor Contacts\n\n###  Investor Relations \n\nIlanit Allen VP of Corporate Communications & Investor Relations [ 908-967-6677 ext. 113 ](tel:908-967-6677) ir@citiuspharma.com\n\n###  Transfer Agent \n\nVStock Transfer LLC 18 Lafayette Place Woodmere, NY 11598 [ 212-828-8436 ](tel:212-828-8436) [www.vstocktransfer.com](https://www.vstocktransfer.com)\n\n###  Auditor \n\nWolf & Company, P.C. 99 High Street Boston, MA 02110\n\n###  Legal Counsel \n\nWyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail Suite 300 Raleigh, NC 27607 [www.wyrick.com](https://www.wyrick.com)\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        }
      ]
    }
  ]
}